From bench to behaviour: The role of lifestyle factors on intraocular pressure, neuroprotection, and disease progression in glaucoma

Kumar, Anika; Ou, Yvonne

doi:10.1111/ceo.14218

Cited by 12 publications

(8 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the inherently limited therapeutic capacity of IOP reduction among patients already in the normotensive IOP range, identifying modifiable factors beyond IOP becomes crucial . Apart from alcohol cessation, other lifestyle interventions, such as aerobic exercise, stress reduction through mindfulness, and a nutrient-rich diet, have been proposed to lower IOP and/or provide neuroprotection . However, longer studies are needed to confirm and assess the sustainability of these effects.…”

Section: Discussionmentioning

confidence: 99%

Visual Impairment Risk After Alcohol Abstinence in Patients With Newly Diagnosed Open-Angle Glaucoma

Jeong,

Kim,

Kang

et al. 2023

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceRecent studies indicate that alcohol consumption is linked to increased intraocular pressure and higher prevalence of open-angle glaucoma (OAG). However, there is insufficient evidence to establish any correlation between alcohol abstinence and improved outcomes in patients with OAG.ObjectiveTo evaluate the association between alcohol consumption status (and its changes) and risk of incident severe visual impairment (VI) or blindness in patients with newly diagnosed OAG.Design, Setting, and ParticipantsThis retrospective, nationwide, population-based cohort study used the Korean National Health Insurance Service’s claims and health examination database to enroll patients who were newly diagnosed with OAG between January 1, 2010, and December 31, 2011, and had been alcohol drinkers before their OAG diagnosis. The cohort was followed up until December 2020. The data were analyzed from February to December 2022.ExposuresThe patients were categorized into 2 groups based on their post–OAG diagnosis alcohol consumption status: sustainers and abstainers. The risks of severe VI or blindness were compared using weighted Cox proportional hazards regression models along with inverse probability of treatment weighting.Main Outcomes and MeasuresIncident severe VI or blindness.ResultsAmong 13 643 patients with newly diagnosed OAG (mean [SD] age, 53.7 [11.9] years; 12 066 men [88.4%]) who were drinkers, 2866 (21.0%) quit drinking after the diagnosis. During 91 366 person-years of follow-up, patients abstaining from alcohol after their OAG diagnosis had a lower risk of severe VI or blindness than did those who had sustained drinking (adjusted hazard ratio [AHR] after inverse probability of treatment weighting, 0.63; 95% CI, 0.45-0.87). Among the sustained drinkers, both mild consumption (&lt;105 g/wk; AHR, 1.52; 95% CI, 1.01-2.28) and moderate to heavy consumption (≥105 g/wk; AHR, 1.78; 95% CI, 1.11-2.86) after OAG diagnosis were associated with higher risk of severe VI or blindness relative to abstainers. Frequent drinking (≥4 d/wk) also was associated with a higher risk of severe VI or blindness (AHR, 2.56; 95% CI, 1.52-4.33) compared with abstinence.Conclusions and RelevanceIn this cohort study of patients with OAG who were drinkers, abstaining from alcohol after an OAG diagnosis was associated with lower risk of severe VI or blindness. These findings suggest that lifestyle interventions, such as alcohol abstinence, could be essential for patients with newly diagnosed OAG.

show abstract

Section: Discussionmentioning

confidence: 99%

Visual Impairment Risk After Alcohol Abstinence in Patients With Newly Diagnosed Open-Angle Glaucoma

Jeong,

Kim,

Kang

et al. 2023

JAMA Netw Open

View full text Add to dashboard Cite

show abstract

“…FoxOs are intimately tied to the pathways of programmed cell death. Blockade of FoxO transcription factor activity can inhibit microglial cell apoptotic death during ROS and Aβ exposure [343,344,[349][350][351], foster the protective effects of metabotropic glutamate receptors [259,352], and prevent neuronal apoptotic cell loss through nicotinamide adenine dinucleotide (NAD + ) precursors [86,162,198,213,[353][354][355][356][357][358]. For example, nicotinamide can block FoxO protein activity [329,359] and is protective through two mechanisms of post-translational modification of FoxO3a [50, 186,317].…”

Section: Mammalian Forkhead Transcription Factors and Multiple Sclerosismentioning

confidence: 99%

Cognitive Impairment in Multiple Sclerosis

Maiese

2023

Bioengineering

View full text Add to dashboard Cite

Almost three million individuals suffer from multiple sclerosis (MS) throughout the world, a demyelinating disease in the nervous system with increased prevalence over the last five decades, and is now being recognized as one significant etiology of cognitive loss and dementia. Presently, disease modifying therapies can limit the rate of relapse and potentially reduce brain volume loss in patients with MS, but unfortunately cannot prevent disease progression or the onset of cognitive disability. Innovative strategies are therefore required to address areas of inflammation, immune cell activation, and cell survival that involve novel pathways of programmed cell death, mammalian forkhead transcription factors (FoxOs), the mechanistic target of rapamycin (mTOR), AMP activated protein kinase (AMPK), the silent mating type information regulation 2 homolog 1 (Saccharomyces cerevisiae) (SIRT1), and associated pathways with the apolipoprotein E (APOE-ε4) gene and severe acute respiratory syndrome coronavirus (SARS-CoV-2). These pathways are intertwined at multiple levels and can involve metabolic oversight with cellular metabolism dependent upon nicotinamide adenine dinucleotide (NAD+). Insight into the mechanisms of these pathways can provide new avenues of discovery for the therapeutic treatment of dementia and loss in cognition that occurs during MS.

show abstract

“…The authors declare that there is no conflict of interest. Jonathan G. Crowston MBBS, PhD 1,2,3 Vicki Chrysostomou PhD…”

Section: Conflict Of Interest Statementmentioning

confidence: 99%

“…We are often asked by our patients whether there is anything over and above taking topical medications that they can do to help their glaucoma. The excellent review in this edition of CEO by Kumar and Ou 1 provides a comprehensive overview of the published evidence on the effects of exercise, caffeine, stress reduction (through mindfulness) and nicotinamide supplementation on IOP and glaucoma. Out of these interventions, the most compelling evidence pertains to the beneficial effects of aerobic exercise.…”

mentioning

confidence: 99%

“Doctor, what else can I do for my glaucoma?” Exercise, nicotinamide and other lifestyle interventions

Crowston

Chrysostomou

Bell

2023

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

From bench to behaviour: The role of lifestyle factors on intraocular pressure, neuroprotection, and disease progression in glaucoma

Cited by 12 publications

References 63 publications

Visual Impairment Risk After Alcohol Abstinence in Patients With Newly Diagnosed Open-Angle Glaucoma

Visual Impairment Risk After Alcohol Abstinence in Patients With Newly Diagnosed Open-Angle Glaucoma

Cognitive Impairment in Multiple Sclerosis

“Doctor, what else can I do for my glaucoma?” Exercise, nicotinamide and other lifestyle interventions

Contact Info

Product

Resources

About